Provide a valuable resource to your clients or customers by linking to this resource page. Just place the following link on your website.
Atogepant is a prescription calcitonin gene-related peptide receptor antagonist used for preventive treatment of migraine in adults. It is sold as Qulipta in the United States. Tablets come in 10 mg, 30 mg, and 60 mg strengths. Dosing differs between episodic and chronic migraine and can change with severe kidney impairment or certain interacting medicines.
read more about atogepant ...Atogepant binds to calcitonin gene-related peptide receptors and blocks CGRP activity. CGRP signaling is involved in migraine biology and pain pathways. Blocking the receptor reduces signaling associated with migraine attacks. Atogepant is taken for prevention rather than as a treatment used to stop an individual migraine attack after symptoms begin.
Atogepant is approved for preventive treatment of migraine in adults. The indication covers episodic and chronic migraine. It is not approved for pediatric patients under current U.S. labeling. Treatment choice and dose depend on migraine pattern, kidney and liver function, interacting medicines, and prior preventive therapy.
For episodic migraine, the recommended dose is 10 mg, 30 mg, or 60 mg once daily. For chronic migraine, the recommended dose is 60 mg once daily. Tablets are taken with or without food. Severe kidney impairment or end-stage kidney disease changes episodic migraine dosing, and use for chronic migraine is not recommended in those patients.
Serious concerns include hypersensitivity reactions, new or worsening high blood pressure, and new or worsening Raynaud's phenomenon. Nausea, constipation, and fatigue or sleepiness are common adverse reactions. Atogepant is avoided in severe liver impairment. Facial swelling, trouble breathing, marked blood pressure changes, or painful color changes in fingers or toes need medical assessment.
Yes. Atogepant is approved for preventive treatment of migraine in adults, including episodic and chronic migraine.
Atogepant is taken once daily. The labeled strength depends on migraine type, kidney function, and interacting medicines.
Yes. Atogepant tablets are taken with or without food.
Yes. New high blood pressure and worsening of existing high blood pressure have been reported during treatment.
Atogepant. MedlinePlus. https://medlineplus.gov/druginfo/meds/a621052.html. Date Accessed September 14, 2026.
DailyMed - QULIPTA (atogepant) tablet. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8c8ab8f4-32bd-497a-befa-70c8a51d8d52. Date Accessed September 14, 2026.
FDA Label - QULIPTA (atogepant) Tablets. https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/215206s013lbl.pdf. Date Accessed September 14, 2026.
QULIPTA (atogepant) Patient Information. https://www.rxabbvie.com/content/dam/rxabbvie/pdf/qulipta_pil.pdf. Date Accessed September 14, 2026.
QULIPTA (atogepant) Prescribing Information. https://www.rxabbvie.com/pdf/qulipta_pi.pdf. Date Accessed September 14, 2026.